La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Investcorp AI Acquisition a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Investcorp AI Acquisition..

Investcorp AI Acquisition (OTC:IVCAF) Azioni, Catena delle Opzioni

Investcorp AI Acquisition Corp is a blank check company.

INVESTCORP AI ACQ CORP A by Investcorp AI Acquisition Corp.

Investcorp AI Acquisition Corp

Disc Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 5 posters presented at the EHA 2025 annual meeting in Milan, Italy. This year's presentations included data from HELIOS, an ongoing open-label extension study of bitopertin in EPP, which showed favorable long-term efficacy and safety with sustained protoporphyrin IX (PPIX) reductions, improvement in quality of life, and improved liver biomarkers. Disc is advancing development and registrational activities for bitopertin in EPP, with plans to submit an NDA in H2 2025. The company has initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP. Disc recently launched a campaign to raise awareness of EPP among physicians, patients, and caregivers with emphasis on the causative role of PPIX accumulation in the disease. Learn more at PPIXisWhy.com.
Disc also presented longer term data from the continuation phase of its Phase 1b trial in MF anemia, showing sustained activity on key biomarkers and durable anemia response among major responders. Enrollment for the Phase 2 RALLY-MF trial of DISC-0974 is ongoing with the exploratory cohort for patients on concomitant momelotinib or pacritinib fully enrolled. The company expects to present initial RALLY-MF data in H2 2025. Additionally, Disc shared an update of the Phase 1 healthy volunteer trial of DISC-3405, initially presented at ASH 2024, which demonstrated deep, sustained reductions in serum iron and meaningful changes in hematologic parameters, establishing proof of mechanism. Based on these data, the company has initiated a Phase 2 trial of DISC-3405 in polycythemia vera (PV). Disc also presented an iron pulse study of DISC-3405 in healthy volunteers which showed inhibition of dietary iron uptake, further confirming the mechanism of action and supporting DISC-3405's potential in diseases of iron overload.
The collection of data presented at EHA adds to the evidence base supporting Disc's continued advancement of all three clinical candidates and provides support for expansion opportunities in new indications. Management will host a call to review these updates on June 16 at 8:00 am ET. Please register for the event on the Events and Presentations page of Disc's website (<a href="https://ir.discmedicine.com/">https://ir.discmedicine.com/</a>)
Bitopertin, DISC-0974, and DISC-3405 are investigational agents and are not approved for use as therapies in any jurisdiction worldwide.
Summary of Poster Presentations
Bitopertin:
HELIOS:
HELIOS is an ongoing Phase 2, open-label, long-term extension trial that enrolled 86 adult and adolescent patients with EPP from the BEACON and AURORA trials. Patients were randomized to receive 20 mg or 60 mg bitopertin in BEACON and 20 mg or 60 mg bitopertin or placebo in AURORA, with all patients transitioning to a 60 mg daily dose of bitopertin in HELIOS.
<ul>
<li>Longer term treatment with bitopertin was associated with sustained reductions in the disease-causing toxin PPIX, with additional benefit for patients receiving the 60 mg dose continuously</li>
<li>Continuous treatment with 60 mg of bitopertin reduced ALT and other exploratory hepatobiliary biomarkers</li>
<li>Nearly all participants reported substantial improvements in quality of life measures</li>
<li>Bitopertin exhibited a favorable longer-term safety profile with up to 2+ years of exposure and similar safety across adults and adolescents with EPP and XLP</li>
</ul>
DISC-0974:
DISC-0974 Phase 1b in MF anemia:
Data from the continuation phase of the Phase 1b trial of DISC-0974 in MF anemia as of October 2024 were presented. This multi-center, open-label trial included patients who were: non-transfusion dependent receiving no transfusions (nTD, n=23), transfusion dependent with low transfusion burden (TD Low, n=5) and transfusion dependent with high transfusion burden (TD High, n=7). The trial was comprised of both patients receiving concomitant JAK inhibitor therapy (n=13) and not receiving JAK inhibitor therapy (n=22).&nbsp;DISC-0974 was administered subcutaneously at 14 mg (n=1), 28 mg (n=7), 50 mg (n=12), 75 mg (n=9), or 100 mg (n=6) every 4 weeks for up to 6 treatments. Long-term results demonstrated:
<ul>
<li>Sustained hepcidin suppression, iron mobilization, and reduction in Zinc PPIX, a measure of iron restricted hemoglobin production</li>
<li>nTD patients:
<ul>
<li>50% of evaluable patients achieved major response of sustained mean hemoglobin increase of ≥1.5 g/dL</li>
<li>Hematologic improvement was durable through the continuation phase</li>
</ul>
</li>
<li>TD Low patients:
<ul>
<li>80% of evaluable patients achieved major response of transfusion independence over 16 weeks</li>
<li>Hematologic improvement was durable, and all major responders remained transfusion independent during the continuation phase</li>
</ul>
</li>
<li>TD High patients:
<ul>
<li>40% of evaluable patients achieved major response of transfusion independence over 12 weeks</li>
<li>1 of 2 patients with a major response entered the continuation phase and remained transfusion independent at Day 225, with follow-up ongoing</li>
</ul>
</li>
<li>DISC-0974 was safe and well-tolerated at all evaluated dose levels &nbsp;</li>
</ul>
DISC-0974 in combination with luspatercept and ESA (mouse model):
The effect of DISC-0974, luspatercept, and ESA as single agents and DISC-0974 combined with luspatercept or ESA on hematological parameters in wild type mice was evaluated. Results showed:
<ul>
<li>Treatment with DBIO-100 (a mouse analog of DISC-0974) suppressed hepcidin, enhanced iron availability, and boosted erythropoiesis in wild-type mice</li>
<li>Combining with DPO (ESA) or RAP-536 (mouse analog of luspatercept) led to additional hematological benefits beyond those agents alone</li>
</ul>
These results demonstrate that DISC-0974 has a distinct mechanism of action among anemia-targeted agents and highlight the potential for synergistic anemia benefits when combining DISC-0974 with other anemia-targeted agents.
DISC-3405:
Phase 1 Healthy Volunteer Study:
Updated SAD/MAD data from the Phase 1 trial of DISC-3405 in healthy volunteers were presented. In the SAD portion of this trial, healthy males and females ages 18 to 65 were given a single dose of placebo (n=10) or DISC-3405 at 75 mg intravenously (IV) (n=6), 37.5 mg subcutaneously (SC) (n=6), 75 mg SC (n=6), 150 mg SC (n=6), or 300 mg SC (n=6). The MAD portion included placebo (n=4), 75 mg SC (n=6), and 150 mg SC (n=6) cohorts dosed every 4 weeks for a total of 2 doses. Consistent with data presented at ASH 2024, results showed:
<ul>
<li>DISC-3405 produced dose-related increases in serum hepcidin with corresponding reductions in serum iron across all dose levels</li>
<li>DISC-3405 resulted in deep reductions in serum iron (ranging from 50-80% from baseline) that were sustained and support a once-monthly SC dosing regimen</li>
<li>Single and repeat dosing of DISC-3405 demonstrated meaningful reductions in hematologic parameters, including reticulocyte hemoglobin, hemoglobin, and hematocrit</li>
<li>DISC-3405 was generally well-tolerated at all evaluated dose levels, with no serious adverse events (AEs), greater than Grade 2 AEs, or AEs leading to study withdrawal</li>
</ul>
These results provide proof of mechanism and support the advancement DISC-3405 into proof of concept studies. Disc has now initiated a Phase 2 trial of DISC-3405 in PV with initial results expected in 2026.
Iron Pulse Study:
Disc conducted an iron pulse study in healthy volunteers to evaluate the effectiveness of DISC-3405 in inhibiting dietary iron uptake. N=8 healthy volunteers received placebo treatment followed by oral ferrous sulfate tablets on two sequential occasions to establish baseline iron absorption profiles. Participants were then given a single 150mg IV dose of DISC-3405, followed by oral ferrous sulfate "iron pulses" on the 2nd and 15th days following treatment. DISC-3405 resulted in an average 94% reduction in iron absorption at Day 2 and 68% at Day 15.
These results confirm the mechanism of DISC-3405 and demonstrate its ability to block dietary iron absorption, supporting the potential for treating diseases associated with iron overload.

Government

News

Regulations

IRON

Disc Medicine Highlights New Clinical Data on Three Drug Candidates for Rare Blood and Iron Disorders, Plans FDA Filing for Bitopertin After EPP Study

Cryptocurrency markets are slipping on Thursday, but the broader investor outlook remains optimistic, driven by growing institutional interest in Bitcoin.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$107,319.73</td>
<td>-1.8%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,749.17</td>
<td>-0.8%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$158.63</td>
<td>-3.8%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.23</td>
<td>-3.4%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1882</td>
<td>-6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001263</td>
<td>-4.6%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction volume decreasing by 14.7% and 16.1%, respectively. Daily active addresses are down by 8.7% and 0.7%, respectively. ETH's exchange netflows are up by 88.3%.</li>
<li>Coinglass data shows 109,114 traders were liquidated in the past 24 hours for $327.18 million.</li>
<li>SoSoValue data shows net inflows of $164.6 million into spot Bitcoin ETFs, while spot Ethereum ETFs saw net inflows of $240.3 million.</li>
</ul>
Trader Notes: Market watcher More Crypto Online highlighted the importance of staying grounded during volatile cycles. Rather than reacting emotionally to dips or headlines, disciplined traders are focusing on key technical zones and upcoming retests — an approach that helps not only to survive the cycle but to grow through it.
Bitcoin hit a key bearish target, according to trader Carl The Moon, who emphasized in his latest update that the recent breakdown below crucial support levels opens the door for further downside.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> has reached our bearish target from yesterday&#39;s post! But considering where the support was broken, <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> might fall even lower. <a href="https://t.co/cXOhAnnMTH">pic.twitter.com/cXOhAnnMTH</a>
&mdash; Carl Moon (@TheMoonCarl) <a href="https://twitter.com/TheMoonCarl/status/1933100973079068817?ref_src=twsrc%5Etfw">June 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Degen Hardy <a href="https://x.com/Degen_Hardy/status/1933109145248707003">highlighted</a> that Bitcoin is nearing the $106,000–$107,000 value area high zone, suggesting a possible retest. 
He remains on the sidelines, with no active long positions, opting to wait for clearer confirmation before making moves.
On the Ethereum front, More Crypto Online is <a href="https://x.com/Morecryptoonl/status/1933101958929256642">watching</a> whether bulls can defend the critical $2,611–$2,772 support zone, which aligns with key wave (4) levels. So far, ETH has shown relative strength compared to BTC, suggesting potential resilience.
Solana is catching attention again — trader Posty predicts a rally toward the $180 mark, pointing to technical strength amid broader market caution.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SOL&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SOL</a> $180 soon <a href="https://t.co/HGYvYqd41t">pic.twitter.com/HGYvYqd41t</a>
&mdash; Posty (@PostyXBT) <a href="https://twitter.com/PostyXBT/status/1933082976939819085?ref_src=twsrc%5Etfw">June 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
As for Dogecoin, trader Tardigrade <a href="https://x.com/TATrader_Alan/status/1933087157545226443">pointed</a> out a repeating pattern on the weekly chart, a series of small rallies leading into major breakouts. He believes the current move may follow this trend, with some market watchers forecasting a potential push toward the $1 milestone.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45887955/bitcoin-hovers-below-110000-is-this-the-calm-before-the-storm">Bitcoin Hovers Below $110,000: Is This The Calm Before The Storm?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Slide On Thursday Morning: What's Going On?

PLRZ

Polyrizon Announces Preclinical Results From Study Evaluating Its Trap & Target Platform Showing Formulation Achieved Targeted Deposition In Upper Regions Of Nasal Cavity

– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML&nbsp;–
– 93% (41/44) and 89% (24/27) CRc observed in NPM1-m and KMT2A-r AML response-evaluable patients, respectively&nbsp;–
– 71% (24/34) and 88% (14/16) CR measurable residual disease (MRD)-negativity observed among responding NPM1-m and KMT2A-r AML patients, respectively –
– 96% (47/49) of NPM1-m and 88% (29/33) KMT2A-r AML patients remain alive and continue on-study –
– Combination was well tolerated with no additive myelosuppression&nbsp;–
– KOMET-017-IC (intensive chemotherapy) and NIC (non-intensive chemotherapy) randomized phase 3 studies (NCT07007312) expected to start in 2H 2025 –
–&nbsp;Kura Oncology&nbsp;to host virtual investor event to discuss results and broader ziftomenib development plan on June 18, 2025 at 4:30pm ET / 1:30pm PT&nbsp;–
SAN DIEGO and TOKYO, June 12, 2025 (GLOBE NEWSWIRE) -- &nbsp;Kura Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>, "Kura"))) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today provided positive updated clinical data from KOMET-007, a Phase 1a/1b trial of ziftomenib, a highly selective oral investigational menin inhibitor, in combination with standards of care in patients with newly diagnosed NPM1-mutant (NPM1-m) and KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). The data for the combination with cytarabine/daunorubicin (7+3) were presented as an oral presentation at the European Hematology Association 2025 Congress (EHA2025) being held in Milan, Italy from June 12-15, 2025.

KURA

Kura Oncology And Kyowa Kirin Report Updated Clinical Data From KOMET-007, Phase 1a/1b Trial Of Ziftomenib, In Patients With Newly Diagnosed NPM1-M And KMT2A-R AML

Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces it has successfully canceled all remaining Series A Warrants pursuant to its letter agreements with the holders of the Series A Warrants, having raised the full amount of capital required to complete the cancellation through its At-The-Market ("ATM") facility.
This follows the Company's May 28, 2025, announcement of binding agreements to cancel the final 172 million Series A Warrants in exchange for $12.2 million. Combined with a tranche canceled earlier in May, the initiative removes 347.2 million shares from potential future dilution, fully eliminating the Series A Warrant overhang.
Incannex CEO Joel Latham commented, "Following increased market liquidity, we specifically utilized our ATM facility to fund the cancellation of all outstanding Series A Warrants. This eliminates a significant source of dilution and leaves Incannex with a clean capital structure ahead of key milestones, including the upcoming topline data readout from our Phase 2 RePOSA trial of IHL-42X for obstructive sleep apnea, expected in July 2025. This action reflects our commitment to disciplined capital management and long-term value creation for shareholders."
IHL-42X is being developed as a potential first-in-class oral therapy for obstructive sleep apnea, a condition affecting millions globally with no FDA-approved drug treatment currently available.

IXHL

Incannex Cancels 347M Warrants to Cut Dilution Ahead of Key Sleep Apnea Trial Results

NIVF

NewGen Says It Plans To Diversify Via Additional Real Estate Investments In Abu Dhabi Pending Potential Transactions To Provide Additional Capital; Co. Executed Term Sheet With Enclave Capital, Which Will Serve As Financial Advisor In Connection With Intent To Raise Capital

America's Car-Mart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMT#NASDAQ">CRMT</a>) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $0.86 by 46.51 percent. This is a 2000 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $370.17 million which beat the analyst consensus estimate of $351.85 million by 5.21 percent. This is a 1.51 percent increase over sales of $364.67 million the same period last year.

Earnings

Earnings Beats

CRMT

America's Car-Mart Q4 EPS $1.26 Beats $0.86 Estimate, Sales $370.17M Beat $351.85M Estimate

NewGen Announces Planned $45M Investment In The UAE Real Estate Market

OKLO: -7% &#x7C; <a href="https://www.benzinga.com//node/45894052">OKLO stock has given up its prior loss. Oklo shares were trading lower after the company announced a $400 million public offering of common stock.</a>
&nbsp;
HYMC: -22% &#x7C; <a href="https://www.benzinga.com//node/45893479">Hycroft Mining Holding shares are trading lower after the company announced a $40 million public offering of units.</a>
&nbsp;
NEHC: 190% &#x7C; <a href="https://www.benzinga.com//node/45900766">New Era Helium's TCDC JV In Talks With Enterprises For AI Infrastructure Expansion In Texas</a>

Movers

Trading Ideas

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

NEHC

OKLO

Market-Moving News for June 12th

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the R<a href="https://www.benzinga.com/topic/rsi">SI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Karat Packaging Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>)</h3>
<ul class="wp-block-list">
<li>On June 11, Karat Packaging announced it priced a secondary offering of 1.5 million shares at $27 per share. The company's stock fell around 14% over the past five days and has a 52-week low of $23.00.</li>
<li>RSI Value: 21</li>
<li>KRT Price Action: Shares of Karat Packaging fell 14.7% to close at $26.40 on Wednesday.</li>
<li>Edge Stock Ratings: 57.33 Momentum score with Value at 66.25. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/KRT"><img loading="lazy" decoding="async" width="407" height="178" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071538/image-182.png" alt="" class="wp-image-947461" style="width:300px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071538/image-182.png 407w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071538/image-182-300x131.png 300w" sizes="(max-width: 407px) 100vw, 407px" /></a></figure>
<h3 class="wp-block-heading">Copart Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 22, Copart reported a third-quarter revenue miss. The company's stock fell around 19% over the past month and <a href="https://www.benzinga.com/quote/CPRT">has a 52-week low</a> of $48.05.</li>
<li>RSI Value: 25.9</li>
<li>CPRT Price Action: Shares of Copart rose 0.4% to close at $50.50 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612">cprt stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612"><img loading="lazy" decoding="async" width="923" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071705/image-183.png" alt="" class="wp-image-947463" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071705/image-183.png 923w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071705/image-183-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071705/image-183-768x691.png 768w" sizes="(max-width: 923px) 100vw, 923px" /></a></figure>
<h3 class="wp-block-heading">Aaon Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NASDAQ">AAON</a>)</h3>
<ul class="wp-block-list">
<li>On May 1, AAON posted upbeat quarterly earnings. Gary Fields, CEO, said, &#8220;We had a strong first quarter. Net sales, gross margin and earnings all experienced quarter-over-quarter improvement. Production of BASX-branded equipment made solid progress as we accelerated backlog conversion, utilizing all four of our major locations, including our new facility in Memphis.&#8221; The company's stock fell around 28% over the past month and has a 52-week<a href="https://www.benzinga.com/quote/AAON"> low of $68.98.</a></li>
<li>RSI Value: 22.6</li>
<li>AAON Ltd Price Action: Shares of AAON fell 3.5% to close at $75.85 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612">AAON shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612"><img loading="lazy" decoding="async" width="865" height="806" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071928/image-185.png" alt="" class="wp-image-947468" style="width:613px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071928/image-185.png 865w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071928/image-185-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071928/image-185-768x716.png 768w" sizes="(max-width: 865px) 100vw, 865px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

AAON

CPRT

Top 3 Industrials Stocks That Could Lead To Your Biggest Gains This Month

The euro has lost its position as the second-largest reserve asset globally, with gold taking its place, the European Central Bank (ECB) stated in its 2025 annual review.
The top European financial institution took notice of a surge in central bank purchases and record-breaking prices of <a target="_blank" href="https://www.benzinga.com/topic/gold" rel="noreferrer noopener">the yellow metal</a>. At 20% of reserves, gold is slowly closing the gap on the U.S. dollar, which leads at 46%.
"Adjusted for inflation, real gold prices in 2024 surpassed their previous peak seen during the 1979 oil crisis. Meanwhile, gold reserves held by central banks stand at levels close to those last seen in the Bretton Woods era (36,000 tons), although they now account for a far smaller share of total gold supply," the ECB said in the <a target="_blank" href="https://www.ecb.europa.eu/press/other-publications/ire/focus/html/ecb.irebox202506_01~f93400a4aa.en.html" rel="noreferrer noopener">review</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45893521" rel="noreferrer noopener">US Embassy Evacuations Spark Middle East Risks, And Markets Are Noticing</a>
The bank has stated the persistent rally into 2025, which has (for now) topped at $3,500 per ounce, driven by a mix of investor interest and persistent official sector demand.
The geopolitical shock of Russia's invasion of Ukraine in 2022 triggered a reassessment of reserve strategies among central banks. Concerns over sanctions and the weaponization of reserve currencies drove a shift toward gold, which has long been viewed as a neutral store of value.
This trend was notable among countries geopolitically aligned with or near China and Russia, many of which began increasing their gold holdings in late 2021.
In response, gold demand from the official sector surged to historic highs. Central banks added over <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/02/43512109/gold-extends-records-as-central-banks-rush-to-buy-bullion-miners-eye-sixth-straight-winning-week" rel="noreferrer noopener">1,000 tons of gold</a> in each of the past three years—more than double the pace seen during the 2010s.
In 2024 alone, official sector purchases represented over 20% of global gold demand, effectively doubling the average share of 10% in the previous decade.
According to recent data from the World Gold Council, Türkiye, India, China, and Poland were the <a target="_blank" href="https://www.gold.org/goldhub/gold-focus/2025/05/indias-gold-market-update-gains-hold-despite-demand-pressure" rel="noreferrer noopener">largest gold buyers</a>, collectively adding over 600 tons since the end of 2021. Interestingly, while India recently became the fourth-largest global economy, Poland is its European counterpart and the only regional outperformer in 2024,<a target="_blank" href="https://think.ing.com/snaps/poland-cee-peers-2024/" rel="noreferrer noopener"> ING research</a> showed.
Boosted gold reserves could help these economies to <a target="_blank" href="https://www.benzinga.com/markets/commodities/25/05/45617358/gold-demand-holds-firm-as-dollar-confidence-wavers" rel="noreferrer noopener">safeguard against de-dollarization</a>, and hedge against inflation and political instability.
Despite gold's impressive climb, its dominance is still constrained by supply limitations and competition from other reserve assets. Notably, the global gold supply is expected to grow by just<a target="_blank" href="https://www.benzinga.com/markets/commodities/25/06/45828108/global-gold-supply-to-grow-1-in-2025-report-shows" rel="noreferrer noopener"> 1% in 2025</a>, while the U.S. dollar money supply (M2) has grown by<a target="_blank" href="https://ycharts.com/indicators/us_m2_money_supply_yoy" rel="noreferrer noopener"> 4.44%</a> in the last 12 months.
Price Watch: SPDR Gold Shares ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) is up 25.6% year-to-date.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/commodities/25/06/45891893/is-the-us-secretly-hoarding-gold-expert-says-do-it-first-tell-the-world-after" target="_blank" rel="noreferrer noopener">Is The U.S. Secretly Hoarding Gold? Expert Says ‘Do It First, Tell the World After'</a></li>
</ul>
Photo by FOTOGRIN via Shutterstock

Macro Economic Events

Commodities

Economics

CurrencyShares British Pound Sterling Trust

GLDM

OUNZ

SGOL

PowerShares DB US Dollar Index Bearish Fund

USDU

PowerShares DB US Dollar Index Bullish Fund

Gold Surpasses Euro To Become Second-Largest Reserve Asset, Still Far Behind Dollar, ECB Says

Karooooo Ltd. ("Karooooo") announced the pricing of an underwritten secondary public offering (the "Offering") of 1,500,000 ordinary shares held by Isaias (Zak) Jose Calisto, Karooooo's chief executive officer (the "Selling Shareholder"), at a price to the public of $50.00 per ordinary share (the "public offering price") for total gross proceeds of approximately $75.0 million. The Offering is expected to close on June 13, 2025, subject to customary closing conditions. In addition, the underwriters of the Offering will have a 30-day option to purchase up to an additional 225,000 ordinary shares from the Selling Shareholder at the public offering price. Karooooo's ordinary shares are listed on the Nasdaq Capital Market under the symbol "KARO."
 &nbsp;

KARO

Karooooo Prices Underwritten Secondary Public Offering Of 1.50M Ordinary Shares Held By CEO Isaias Jose Calisto At $50/Shr For Total Gross Proceeds Of ~$75M

Mark Cuban reshared a post supporting Rep. Ro Khanna&#8216;s (D-Calif.) &#8220;Progressive Deficit Reduction Plan,&#8221; which aims to slash the U.S. deficit by $12 trillion over the next decade.
What Happened: Khanna detailed the plan, emphasizing $2.4 trillion in spending cuts as a cornerstone of the initiative. The plan, unveiled on June 10, 2025, seeks to reduce the deficit-to-GDP ratio to 3% by 2034, well below the historical average of 3.8%.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Republican budget adds $2.4 trillion. This would be 7-8.6 percent of GDP. Our bond markets are fearful that interest rates will go up, and the Fed will have to buy more Treasury bonds, making us all poorer. The historical average of deficit to GDP is under 4 percent. My plan… <a href="https://t.co/CuXUpqSagN">pic.twitter.com/CuXUpqSagN</a>
&mdash; Rep. Ro Khanna (@RepRoKhanna) <a href="https://twitter.com/RepRoKhanna/status/1932453771633688883?ref_src=twsrc%5Etfw">June 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Key components of the spending cuts include modernizing the military and reforming contracting to save $850 billion.
The plans also aim to eliminate Medicare Advantage upcoding and fraud to save $830 billion.
&#8220;Republicans want to slash nearly $1T from Medicare and Medicaid—ripping away healthcare from 16 millions ordinary Americans to pay for tax breaks for billionaires. Instead, we could save $830 billion by ending corporate profiteering. That means cracking down on Medicare Advantage fraud and abuse like upcoding, where private insurers overbill taxpayers and pocket the difference,&#8221; his statement said.
Other key areas of spending cuts include negotiating Medicare drug prices for $200 billion in savings, ending fossil fuel subsidies to save $170 billion, and implementing smarter government procurement for an additional $333 billion.
These measures aim to address inefficiencies and corporate profiteering while investing in critical areas like technology, diplomacy, and healthcare.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/25/06/45886571/gary-blacks-2021-tsla-stock-exit-dodged-a-30-drop-can-valuation-discipline-outsmart-teslas-2025-" target="_blank" rel="noreferrer noopener">Gary Black's 2021 TSLA Stock Exit Dodged A 30% Drop: Can Valuation Discipline Outsmart Tesla's 2025 Robotaxi Hype</a>
Why It Matters: After President Donald Trump was elected, he announced the formation of the Department of Government Efficiency, or DOGE, under the leadership of Elon Musk. It was aimed at reducing wasteful government spending.
According to the <a href="https://doge.gov/savings">official website</a>, its &#8220;estimated&#8221; savings stand at $180 billion.
However, evaluations and independent analyses by many firms and publications have revealed inaccuracies in Musk&#8217;s reported figures. Additionally, federal spending under Trump in 2025 has kept increasing.
While this &#8216;Progressive Deficit Reduction Plan&#8217; challenges the Republican plan to reduce spending, its viability will only be put to the test upon execution.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Thursday. The SPY was down 0.39% at $599.01, while the QQQ declined 0.41% to $530.23, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45899298/automotive-and-apparel-companies-absorbed-tariff-costs-amid-better-than-expected-may-cpi-print-but-dont-expect-that-to-continue-says-expert">Automotive And Apparel Companies &#8216;Absorbed Tariff Costs&#8217; Amid Better Than Expected May CPI Print: &#8216;But Don&#8217;t Expect That To Continue,&#8217; Says Expert </a></li>
</ul>
Photo Courtesy: Kathy Hutchins On Shutterstock

Mark Cuban Backs Ro Khanna's $12 Trillion 'Progressive Deficit Reduction Plan,' Targeting Medicare Fraud And Military Spending

Ultrawide and simplified to deliver a more streamlined and immersive experience at the helm

GRMN

Garmin Unveils GPSMAP 15x3 With Ultrawide 15-Inch Touchscreen For Streamlined And Immersive Helm Experience

Strategic Partnership with The Baldwin Group&nbsp;
On June 11, 2025, Hippo entered into an agreement with The Baldwin Group to form a strategic partnership. Under the terms of the agreement:
<ul>
<li>Hippo will distribute its new construction homeowners product through Baldwin's subsidiary, Westwood Insurance Agency's industry-leading homebuilder network. This will allow Hippo to accelerate the growth of its New Homes business by accessing three times as many new construction homebuyers.</li>
<li>Baldwin will purchase Hippo's existing homebuilder distribution network for $100 million.</li>
<li>Hippo's hybrid fronting platform, Spinnaker, will build upon its decade-long support of Baldwin's MSI Renters and MSI Homeowners programs by providing capacity to a broader range of Baldwin's MGA programs.</li>
</ul>

BWIN

HIPO

Baldwin Group's Westwood To Purchase Hippo's Existing Homebuilder Distribution Network For $100M

LFCR

Lifecore Biomedical Receives Early $10M Payout From Filler Sale, Boosting Balance Sheet And Supporting $300M Revenue Capacity Strategy

INVA

Innoviva Says FDA Grants Priority Review For Zoliflodacin New Drug Application For Treatment Of Uncomplicated Gonorrhea And Assigns Target PDUFA Date of December 15

2028 Financial Targets:
The company is also introducing 2028 financial targets of:
<ul>
<li>Gross written premium of greater than $2 billion</li>
<li>Adjusted net income of greater than $125 million</li>
<li>Adjusted return on equity of greater than 18%</li>
</ul>

Guidance

Hippo Expects 2028 Gross Written Premium Greater Than $2B, Adj Net Income Over $125M, And Adj ROE Greater Than 18%

HC Wainwright &amp; Co. analyst Robert Burns maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $40 to $47.

Price Target

Analyst Ratings

EXEL

HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $47

AGAE

Allied Gaming & Entertainment Sues Knighted Group In Federal Court Alleging Undisclosed Stock Accumulation And Board Takeover Scheme Ahead Of August 2025 Vote

Comments

Investcorp AI Acquisition

Investcorp AI Acquisition (IVCAF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO